#USA #Fremont #Alamar Biosciences #Biomarker Testing #NULISAqpcr

Alamar Biosciences Unveils NULISAqpcr™ Custom Assay Development Kit

In a significant advancement for the biomarker testing landscape, Alamar Biosciences has officially introduced the NULISAqpcr Custom Assay Development Kit. This state-of-the-art product aims to enhance the development of innovative biomarker tests tailored for clinical research.

Located in Fremont, California, Alamar Biosciences specializes in precision proteomics, focusing on the rapid detection of diseases. The newly launched kit allows scientists to design highly sensitive and accurate biomarker tests that cater to specific research demands, thus broadening the application of the NULISA™ technology to a larger biomarker research community.

The NULISAqpcr Custom Assay Development Kit provides unparalleled flexibility, enabling researchers to create targeted tests based on their own antibodies while ensuring exceptional sensitivity and reproducibility. This customizable kit is particularly beneficial for fields that require high sensitivity and broad dynamic ranges, such as immunology and neurology. It facilitates smooth workflows from antibody conjugation to automated NULISAqpcr steps on the ARGO™ HT machine, setting a new benchmark for developing single-plex tests in-house.

Dr. Yuling Luo, the founder, chairman, and CEO of Alamar Biosciences, expressed that, "The Custom Assay Development Kit directly responds to the increasing demand from researchers eager to leverage our cutting-edge NULISA technology for developing high-performance biomarker tests for translational and clinical research." He emphasized that the introduction of this kit marks a significant milestone in their mission to create a transformative ecosystem supporting precision proteomics.

By launching the NULISAqpcr Custom Assay Development Kit, Alamar further solidifies its commitment to fostering innovation and supporting the scientific community with next-generation solutions. The kit is currently available for order, with deliveries expected to commence in the second quarter.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company dedicated to precision proteomics aimed at the swiftest possible disease detection. Its proprietary NULISA™ platform, along with the ARGO™ HT system, seamlessly integrates with the latest advancements in genomics, achieving one-digit attomolar detection sensitivity that significantly surpasses the most sensitive protein detection technologies available in the market today.

For further information, visit alamarbio.com. Additionally, you can view an introductory video about the product here.

Alamar's consistent innovation sets a new standard in protein analysis, potentially transforming how biomarker tests are conducted in clinical settings. With these new tools, researchers can look forward to more versatile and precise testing options that may lead to earlier and more accurate disease detections.